Long-term overall survival and prognostic score predicting survival: the IMPACT study in precision medicine.

ABSTRACT:

Background

In 2007, we initiated IMPACT, a precision medicine program for patients referred for participation in early-phase clinical trials. We assessed the correlation of factors, including genomically matched therapy, with overall survival (OS).

Patients and methods

We performed molecular profiling (Clinical Laboratory Improvement Amendments) (genes ≤ 182) for patients with lethal/refractory advanced cancers referred to the Phase 1 Clinical Trials Program. Matched therapy, if available, was selected on the basis of genomics. Clinical trials varied over time and included investigational drugs against various targets (single agents or combinations). Patients were followed up for up to 10 years.

Results

Of 3487 patients who underwent tumor molecular profiling, 1307 (3

SUBMITTER: Tsimberidou AM 

PROVIDER: S-EPMC6937824 | biostudies-literature | 2019 Dec

REPOSITORIES: biostudies-literature